The Tollbooth Most Investors Miss
Porter Stansberry’s Ignition Point pitch leans on a barbell of royalty “tollbooth” names and speculative drug developers. Halozyme (HALO) is one of the tollbooth companies that appears in the context of the pitch, though it is not a confirmed formal pick. Its job is simple to describe and hard to replicate: it owns a technology that lets big drugmakers change how their injectable biologics are delivered, and it collects a royalty every time one of those drugs is sold.
The technology is called ENHANZE, and it is built on a human enzyme known as hyaluronidase. In plain terms, the enzyme breaks down a gel-like barrier under the skin so that large-volume drugs that once required a slow intravenous drip can instead be given as a quick subcutaneous injection.
How ENHANZE Works
A biologic medicine is a large, delicate molecule. It usually cannot be squeezed through a needle in a concentrated form without hurting the patient or degrading the drug. ENHANZE temporarily loosens the tissue under the skin so a larger volume can be absorbed quickly and comfortably. The patient gets a short injection instead of a long IV session, and the drugmaker gets a more convenient product that patients are more likely to take.
Halozyme licenses ENHANZE to major pharmaceutical partners, who then pair it with their own drugs. In return, Halozyme earns a royalty on sales of the resulting products. That is the tollbooth: Halozyme does not run the late-stage trials for those drugs or carry their regulatory risk, but it shares in the upside every time a dose is sold.
The Royalty Model in Context
This is the same capital-light logic Porter lays out in his broader Royalty Riches teardown. A royalty owner puts up capital or technology once, then collects a top-line slice while someone else carries the expensive side of the business. Halozyme’s version sits inside biotech rather than minerals or oil, but the shape of the economics is the same.
The difference matters. A drug developer can lose everything if a trial fails, which is exactly what happened to Novartis’s pelacarsen in the Lp(a) race on September 4, 2026. A royalty owner like Halozyme is spread across many partnered drugs, so a single failure does not sink the business. We contrast that with the single-molecule tollbooth names in our Ligand Pharmaceuticals piece.
What to Watch
The catch is concentration. ENHANZE’s royalty stream depends on a handful of large partnered products, so the model is only as durable as the pipeline behind it. If a flagship partnered drug loses exclusivity or faces competition, the royalty that Halozyme collects from it shrinks.
That is the honest trade-off in any tollbooth. The model is attractive because it sidesteps trial risk, but it still lives and dies by the success of other companies’ drugs. Halozyme has to keep signing new ENHANZE partners to replace the royalties that inevitably mature.
The Bottom Line
Halozyme is a useful lens for understanding the “tollbooth” half of Porter’s barbell, even though it is not a confirmed pick in the pitch. It converts drug-delivery technology into a recurring royalty stream, which is the exact ballast the thesis is built around. Whether it deserves a spot in a portfolio depends on the depth of its partner roster and the staying power of its flagship products.
ENHANZE in Practice
Think about what ENHANZE actually changes for a patient. A large biologic, the kind used to treat cancer or autoimmune disease, has historically meant a needle into a vein for an hour or more in a clinic. With ENHANZE, the same drug can often be reformulated as a quick injection under the skin, given in minutes and sometimes self-administered at home.
That convenience is not cosmetic. It changes how a drug competes. A product that patients can take in minutes instead of hours, at home instead of a clinic, wins market share against rivals that cannot offer the same. For the drugmaker, the injection version often holds up longer against competition, because the formulation and the delivery technology are harder to copy than the underlying molecule.
For Halozyme, each of those wins translates directly into royalty revenue. The more its partners’ injectable versions sell, the more Halozyme earns, with no trial risk of its own. That is the tollbooth in action: the technology multiplies the value of someone else’s drug, and Halozyme takes a cut of the extra sales.
The model is not without limits. ENHANZE works best with biologics that are hard to deliver subcutaneously, and the number of new partner deals each year is the clearest signal of future royalty growth. When that pipeline of new agreements slows, so does the long-run compounding.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.